Single center experience with alpelisib-fulvestrant in heavily pretreated women with HR(+), HER-2 (-) metastatic breast cancer.

被引：0
|
作者：
Tryfonopoulos, Dimitrios
Tzouda, Vasiliki
Zouki, Dionysia
Kyriakidou, Athina
Sarris, Evangelos
Grivas, Anastasios
Gouveris, Panagiotis
Papaxoinis, George
Demiri, Stamatina G.
机构：
[1] St Savas AntiCanc Hosp, Athens, Greece
[2] Hosp Agios Savvas, Athens, Greece
[3] Agios Savvas Canc Hosp, Athens, Greece
[4] Agios Savvas Anticanc Hosp, Athens, Greece
[5] Agios Savvas Anticanc Hosp, Athens, CT, Greece
[6] Agios Savvas Anticanc Hosp, Dept Med Oncol 2, Athens, Greece
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13034
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Trastuzumab plus paclitaxel in HER-2 positive metastatic breast cancer: A single institutional experience
    Capobianco, A. M. L.
    Di Leo, P.
    Bochicchio, A. M.
    Coccaro, M.
    Romano, G.
    Tartarone, A.
    Ardito, R.
    Musto, C.
    Barone, M.
    Guarigli, R.
    Di Renzo, N.
    ANNALS OF ONCOLOGY, 2005, 16 : 141 - 142
  • [22] Developing a prediction model for benefit from fulvestrant in heavily pretreated metastatic breast cancer patients
    Amir, E.
    Freedman, O. C.
    Chia, S.
    Petrella, T.
    Dent, S.
    Tonkin, K.
    Ahmad, I.
    Rayson, D.
    Dranitsaris, G.
    Clemons, M.
    BREAST CANCER RESEARCH, 2009, 11 : S19 - S19
  • [23] Developing a prediction model for benefit from fulvestrant in heavily pretreated metastatic breast cancer patients
    E Amir
    OC Freedman
    S Chia
    T Petrella
    S Dent
    K Tonkin
    I Ahmad
    D Rayson
    G Dranitsaris
    M Clemons
    Breast Cancer Research, 11
  • [24] Efficacy of fulvestrant in relation to prolactin (PRL) levels in heavily pretreated metastatic breast cancer (MBC)
    Lissoni, P.
    Ardissoia, A.
    Vaghi, M.
    Colombo, I.
    Amoff, J.
    Gardani, G.
    Villa, F.
    ANNALS OF ONCOLOGY, 2006, 17 : XI13 - XI13
  • [25] Fulvestrant in metastatic breast cancer: Safety, efficacy, and role as mainteinance therapy for heavily pretreated patients
    Carillio, G.
    Scandurra, G.
    Aiello, R.
    Taibi, E.
    Mazzola, A.
    Ali, M.
    Bagnato, S.
    Fallica, G.
    Chiarenza, M.
    Caruso, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [26] Eribulin and carboplatin in heavily pretreated patients with metastatic breast cancer: A single institution experience.
    Romano, Patricia Martin
    Baraibar, Iosune
    Fernandez-Hidalgo, Oscar
    Santisteban, Marta
    Espinos, Jaime
    Salas, Diego
    Sala, Pablo
    Gardeazabal, Itziar
    Zubiri Oteiza, Leyre
    Aramendia, Jose M.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (28)
  • [27] Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer.
    Ates, Ozturk
    Babacan, Taner
    Sarici, Furkan
    Kertmen, Neyran
    Cenoli, Alma
    Akin, Serkan
    Karakas, Yusuf
    Kilickap, Saadettin
    Aksoy, Sercan
    Ozisik, Yavuz Yasin
    Altundag, Kadri
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [28] A Cohort Study of the Antitumor Efficacy and Toxicity Profile of Alpelisib for Metastatic or Locally Advanced HR+, HER2-Breast Cancer: A Single-Institution Experience
    Sarfraz, Humaira
    Bari, Shahla
    Whiting, Junmin
    Sur, Melissa
    Mo, Qianxing
    Armitage, Melissa
    Costa, Ricardo L. B.
    ONCOLOGY, 2024, 102 (05) : 414 - 424
  • [29] Palbociclib in highly pretreated metastatic ER-positive HER-2 negative breast cancer
    Hoste, Griet
    Punie, Kevin
    Wildiers, Hans
    Neven, Patrick
    Berteloot, Patrick
    Van Nieuwenhuysen, Els
    Han, Sileny
    Concin, Nicole
    Salihi, Rawand
    Lefever, Inge
    Vergote, Ignace
    CANCER RESEARCH, 2018, 78 (04)
  • [30] Developing a prediction model for benefit from fulvestrant in heavily pretreated metastatic breast cancer (MBC) patients
    Amir, E.
    Freedman, O. C.
    Dranitsaris, G.
    Napolskikh, J.
    Chia, S.
    Petrella, T.
    Dent, S.
    Kumar, R.
    Fralick, M.
    Clemons, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345